CHEN, Young K.,KANOUNI, Toufike,KALDOR, Stephen W.,STAFFORD, Jeffrey Alan,VEAL, James Marvin,TAVARES-GRECO, Paula Alessandra,KREILEIN, Matthew Michael
申请号：
EP16863111
公开号：
EP3371152A4
申请日:
2016.11.04
申请国别(地区):
EP
年份:
2019
代理人:
摘要：
Described herein are amorphous and crystalline forms of pharmaceutically acceptable salts of the lysine specific demethylase-1 inhibitor 4-[2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl]-2-fluorobenzonitrile. Also described are pharmaceutical compositions suitable for administration to a mammal that include the lysine specific demethylase-1 inhibitor, and methods of using the lysine specific demethylase-1 inhibitor for treating diseases or conditions that are associated with lysine specific demethylase-1 activity.
